Agios Pharmaceuticals Management
Management criteria checks 4/4
Agios Pharmaceuticals' CEO is Brian Goff, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is $3.42M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.095% of the company’s shares, worth $1.76M. The average tenure of the management team and the board of directors is 2.3 years and 7.9 years respectively.
Key information
Brian Goff
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 23.4% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.09% |
| Management average tenure | 2.3yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
Sep 07Agios submits mitapivat application in U.S. for pyruvate kinase deficiency
Jun 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Compensation vs Market: Brian's total compensation ($USD3.42M) is below average for companies of similar size in the US market ($USD5.66M).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Goff (54 yo)
1.8yrs
Tenure
US$3,416,453
Compensation
Mr. Brian M. Goff, M.B.A. is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been Executive Vice President at Alexion Pharmaceuticals, Inc. since June 01, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$3.42m | 0.095% $ 1.8m | |
| Chief Financial Officer | 1.7yrs | US$1.21m | 0.026% $ 485.1k | |
| Corporate Secretary & Chief Legal Officer | 2.3yrs | US$1.93m | 0.065% $ 1.2m | |
| Chief Medical Officer and Head of Research & Development | 2.7yrs | US$2.87m | 0.069% $ 1.3m | |
| Chief Commercial Officer | 1.3yrs | US$3.73m | 0.023% $ 432.6k | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$333.51k | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Principal Accounting Officer | 2.8yrs | no data | 0.0051% $ 94.3k | |
| Chief Technical Operations Officer | 6.9yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: AGIO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$3.42m | 0.095% $ 1.8m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$333.51k | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chair of the Board of Directors | 6.4yrs | US$447.25k | 0.24% $ 4.5m | |
| Independent Director | less than a year | US$663.68k | no data | |
| Member of Scientific Advisory Board | 15.3yrs | no data | no data | |
| Lead Independent Director | 9.4yrs | US$440.95k | 0.014% $ 253.1k | |
| Independent Director | 14.8yrs | US$417.25k | 0.83% $ 15.5m | |
| Member of Scientific Advisory Board | 15.5yrs | no data | no data | |
| Independent Director | 1.8yrs | US$419.91k | 0.0040% $ 75.2k |
7.9yrs
Average Tenure
64yo
Average Age
Experienced Board: AGIO's board of directors are considered experienced (7.9 years average tenure).